Chimerism Analysis in the Pediatric Setting Susanne Kricke, Lana Mhaldien, Rozendo Fernandes, Charizel Villanueva, Alistair Shaw, Paul Veys, Stuart Adams The Journal of Molecular Diagnostics Volume 20, Issue 3, Pages 381-388 (May 2018) DOI: 10.1016/j.jmoldx.2018.02.003 Copyright © 2018 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions
Figure 1 Example data plots from randomly selected samples of whole blood (WB); bone marrow (BM); and cell fractions CD3+, CD15+, and CD19+, comparing quality of peak height and signal strength of the short tandem repeat markers vWA and D3S1358. A and B: vWA marker using the PowerPlex 16 System (A) and the GenePrint 24 System (B) (Promega UK, Southampton, UK). C and D: D3S1358 marker using PowerPlex 16 (C) and GenePrint 24 (D). al, allele; ar, area; sz, size. The Journal of Molecular Diagnostics 2018 20, 381-388DOI: (10.1016/j.jmoldx.2018.02.003) Copyright © 2018 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions
Figure 2 Results of chimerism analysis of samples of bone marrow; whole blood (including samples from the UK National External Quality Assessment Scheme); and cell fractions CD3+, CD15+, and CD19+, and their corresponding DNA samples, with line of best fit (dotted lines). The Journal of Molecular Diagnostics 2018 20, 381-388DOI: (10.1016/j.jmoldx.2018.02.003) Copyright © 2018 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions
Figure 3 Results of purity assessment for cell fractions CD3+ and CD19+, and their corresponding DNA samples, with line of best fit (dashed line). The Journal of Molecular Diagnostics 2018 20, 381-388DOI: (10.1016/j.jmoldx.2018.02.003) Copyright © 2018 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions